Pre-made Bivatuzumab benchmark antibody (Whole mAb, anti-CD44 therapeutic antibody, Anti-CDW44/CSPG8/ECMR-III/HCELL/HUTCH-I/IN/LHR/MC56/MDU2/MDU3/MIC4/Pgp1 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Anti-CD44 therapeutic antibody (Pre-made Bivatuzumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Bivatuzumab (previously BIWA 4) is a humanized monoclonal antibody against CD44 v6.[1][2]
| Products Name (INN Index) | Pre-Made Bivatuzumab Biosimilar, Whole Mab, Anti-Cd44 Antibody: Anti-CDW44/CSPG8/ECMR-III/HCELL/HUTCH-I/IN/LHR/MC56/MDU2/MDU3/MIC4/Pgp1 therapeutic antibody |
|---|---|
| INN Name | bivatuzumab |
| Target | CD44 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 – kappa |
| VD LC | IgG1 – kappa |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Boehringer Ingelheim Pharmaceuticals (Ridgefield CT USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD44 |
| Package |
